SG11201811345TA - Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections - Google Patents

Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections

Info

Publication number
SG11201811345TA
SG11201811345TA SG11201811345TA SG11201811345TA SG11201811345TA SG 11201811345T A SG11201811345T A SG 11201811345TA SG 11201811345T A SG11201811345T A SG 11201811345TA SG 11201811345T A SG11201811345T A SG 11201811345TA SG 11201811345T A SG11201811345T A SG 11201811345TA
Authority
SG
Singapore
Prior art keywords
suite
achaogen
san francisco
tower place
international
Prior art date
Application number
SG11201811345TA
Inventor
Kevin Krause
Daniel Cloutier
Allison Komirenko
Ian Friedland
Ryan Cirz
Adrian Jubb
Logan ANDREWS
Original Assignee
Achaogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achaogen Inc filed Critical Achaogen Inc
Publication of SG11201811345TA publication Critical patent/SG11201811345TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11101111 0 11101 HOE 3E1 0 01111110111 OM 11101110110 11110 1111 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2018/013870 Al 18 January 2018 (18.01.2018) WIP0 I PCT (51) International Patent Classification: JUBB, Adrian; c/o Achaogen, Inc., 1 Tower Place, Suite A61K 31/424 (2006.01) A61P 13/02 (2006.01) 300, South San Francisco, CA 94080 (US). ANDREWS, A61K 31/545 (2006.01) A61P 7/00 (2006.01) Logan; c/o Achaogen, Inc., 1 Tower Place, Suite 300, South A61K 45/06 (2006.01) A61P 17/02 (2006.01) San Francisco, CA 94080 (US). A61P 31/04 (2006.01) A61P 27/16 (2006.01) A61P 11/00 (2006.01) (74) Agent: POTTER, Karen et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA (21) International Application Number: 92130-2040 (US). PCT/US2017/042021 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 13 July 2017 (13.07.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (30) Priority Data: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/362,293 14 July 2016 (14.07.2016) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/465,051 28 February 2017 (28.02.2017) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicant: ACHAOGEN, INC. [US/US]; 1 Tower Place, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Suite 300, South San Francisco, CA 94080 (US). (84) Designated States (unless otherwise indicated, for every (72) Inventors: KRAUSE, Kevin, Michael; c/o Achaogen, kind of regional protection available): ARIPO (BW, GH, Inc., 1 Tower Place, Suite 300, South San Francisco, CA GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 94080 (US). CLOUTIER, Daniel, John; c/o Achaogen, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Inc., 1 Tower Place, Suite 300, South San Francisco, CA TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 94080 (US). KOMIRENKO, Allison, Seiko; c/o Achao- EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, gen, Inc., 1 Tower Place, Suite 300, South San Francis- MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, co, CA 94080 (US). FRIEDLAND, Ian; c/o Achaogen, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Inc., 1 Tower Place, Suite 300, South San Francisco, CA KM, ML, MR, NE, SN, TD, TG). 94080 (US). CIRZ, Ryan; c/o Achaogen, Inc., 1 Tower Place, Suite 300, South San Francisco, CA 94080 (US). Title: COMBINATION OF CEFTIBUTEN AND CLAVULANIC ACID FOR USE IN THE TREATMENT OF BACTERIAL = (54) INFECTIONS FIG. 4A PIXIE of AECOI='7S with ceftibuten 42 1,./ .): a d clavulanate (I peirti) \"4*- t no eta -tite. C115:CLA i oo atu A- CTS:CLA /CM , -÷ CTE:CLA i Cla 1-1 © IN GC M Il ----- (57) : Provided herein are combinations of (a) ceftibuten or a pharmaceutically acceptable salt thereof, or a hydrate of the GC 1-1 foregoing; and (b) clavulanic acid, or a pharmaceutically acceptable salt thereof for use in a method of treating or preventing a bacterial © infection. Also provided are pharmaceutical compositions, articles of manufacture, and kits comprising a) ceftibuten or a pharmaceu- el tically acceptable salt thereof, or a hydrate of the foregoing; and (b) clavulanic acid, or a pharmaceutically acceptable salt thereof, and ( ) 1.6 uses thereof. [Continued on next page] WO 2018/013870 Al MIDEDIMOMOIDEIRDERIONIEMIOMMOIMMEHOM Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of he earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))
SG11201811345TA 2016-07-14 2017-07-13 Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections SG11201811345TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662362293P 2016-07-14 2016-07-14
US201762465051P 2017-02-28 2017-02-28
PCT/US2017/042021 WO2018013870A1 (en) 2016-07-14 2017-07-13 Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections

Publications (1)

Publication Number Publication Date
SG11201811345TA true SG11201811345TA (en) 2019-01-30

Family

ID=59485421

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811345TA SG11201811345TA (en) 2016-07-14 2017-07-13 Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections

Country Status (12)

Country Link
US (1) US10624899B2 (en)
EP (1) EP3484472A1 (en)
JP (1) JP2019527214A (en)
KR (1) KR20190039137A (en)
CN (1) CN109715156A (en)
AU (1) AU2017295866A1 (en)
BR (1) BR112019000453A2 (en)
CA (1) CA3028452A1 (en)
IL (1) IL264232A (en)
PH (1) PH12019500083A1 (en)
SG (1) SG11201811345TA (en)
WO (1) WO2018013870A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3478693T (en) 2016-06-30 2021-10-25 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
US12016868B2 (en) 2018-04-20 2024-06-25 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN112400024B (en) * 2018-06-01 2024-04-09 比奥拉治疗股份有限公司 Device and system for gastrointestinal microbiome detection and processing
CA3212788A1 (en) * 2021-04-05 2022-10-13 Qpex Biopharma, Inc. Ceftibuten dosing regimens
US20240327426A1 (en) * 2021-07-01 2024-10-03 Qpex Biopharma, Inc. Crystalline forms of ceftibuten
CN113350337B (en) * 2021-07-07 2022-07-19 中国海洋大学 Composition of clavulanic acid and aztreonam for inhibiting multidrug-resistant bacteria and application of composition
CN115778949A (en) * 2022-12-15 2023-03-14 复旦大学附属华山医院 Composition and medicine for inhibiting Klebsiella pneumoniae producing KPC enzyme and application thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE41109B1 (en) 1974-04-20 1979-10-24 Beecham Group Ltd Novel -lactam antibiotic from streptomyces clavuligerus
US4529720A (en) 1974-04-20 1985-07-16 Beecham Group, P.L.C. Antibiotic from Streptomyces clavulicerus
US4110165A (en) 1974-04-20 1978-08-29 Beecham Group Limited Process for the production of clavulanic acid
US6048977C1 (en) 1975-04-17 2001-10-16 Smithkline Beecham Plc Clavulanic acid and salts thereof
NZ189022A (en) 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
US5679789A (en) 1987-01-29 1997-10-21 Beecham Group, P.L.C. Pharmaceutical compositions comprising potassium clavulanate and methods of using them
EP0680322B1 (en) * 1993-01-22 2000-07-05 Smithkline Beecham Plc Use of clavulanate and an antibacterial compound for the treatment of infections
GB9401969D0 (en) 1994-02-02 1994-03-30 Smithkline Beecham Plc Process
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9500977D0 (en) 1995-01-19 1995-03-08 Smithkline Beecham Plc Novel process
US20030109503A1 (en) 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
US6177421B1 (en) 1999-05-04 2001-01-23 Fuisz International Ltd. Amoxicillin and clavulanate composition
JP2002535353A (en) 1999-01-29 2002-10-22 ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク Pharmaceutical composition
WO2001087891A1 (en) 2000-05-13 2001-11-22 Smithkline Beecham P.L.C. Process for the purification of a salt of clavulanic acid
WO2002005850A2 (en) 2000-07-19 2002-01-24 Pitmy International N.V. Enhancement of the action of anti-infective agents
US20130059774A1 (en) 2000-08-01 2013-03-07 Mahesh Vithalbhai Patel Efflux pump inhibitors
DE10153078A1 (en) 2001-10-30 2003-05-22 Degussa Use of granules based on pyrogenic silicon dioxide in pharmaceutical compositions
US7815936B2 (en) 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
DE10304403A1 (en) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Process for the preparation of an oral dosage form with immediate disintegration and drug release
PT1644024T (en) 2003-06-06 2019-10-24 Univ Texas Antimicrobial flush solutions
DE10341264A1 (en) 2003-09-04 2005-03-24 Grünenthal GmbH Melt-formulated, multiparticulate oral dosage form
US20050175695A1 (en) 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
FR2872044B1 (en) 2004-06-28 2007-06-29 Flamel Technologies Sa PHARMACEUTICAL FORMULATION BASED ON ANTIBIOTICS IN THE MICROCAPSULAR FORM
FR2878159B1 (en) 2004-11-24 2008-10-17 Flamel Technologies Sa ORAL MEDICATION WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE IN MULTIMICROCAPSULAR FORM
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
US20060222692A1 (en) 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
FR2891459B1 (en) 2005-09-30 2007-12-28 Flamel Technologies Sa MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE INGREDIENT AND ORAL GALENIC FORM COMPRISING THE SAME
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007129176A2 (en) * 2006-04-28 2007-11-15 Wockhardt Ltd Improvements in therapy for treating resistant bacterial infections
WO2007128349A1 (en) 2006-05-10 2007-11-15 Evonik Degussa Gmbh Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
CN101129381B (en) 2006-08-25 2012-02-01 天津和美生物技术有限公司 Antibiotic compound containing beta-lactam antibiotic and ion chelating agent
CN101129382B (en) 2006-08-25 2013-12-25 天津和美生物技术有限公司 Antibiotic compound containing beta-lactam antibiotic and buffering component
DE102007009242A1 (en) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets with enteric-coated matix
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
TR200909787A2 (en) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Pharmaceutical formulations containing a third generation cephalosporin and clavulanic acid.
EP2536408A1 (en) 2010-02-16 2012-12-26 Wockhardt Research Centre Efflux pump inhibitors
US20130129791A1 (en) 2010-05-04 2013-05-23 Mahmut Bilgic Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
WO2011139253A2 (en) 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical compositions comprising ceftibuten
WO2011142731A2 (en) 2010-05-14 2011-11-17 Mahmut Bilgic Formulations comprising a third generation cephalosporin and clavulanic acid
WO2011138402A1 (en) 2010-05-05 2011-11-10 Check-Points Holding B.V. Assays, compositions and methods for detecting drug resistant micro-organisms
EP2575781A1 (en) 2010-06-03 2013-04-10 Mahmut Bilgic Production method for the effervescent formulation comprising cephalosporin and potassium clavulanate
TR201009167A2 (en) 2010-11-05 2012-05-21 Bi̇lgi̇ç Mahmut Pharmaceutical granules containing cephalosporin.
WO2013109225A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical tablet formulations comprising ceftibuten
TWI641372B (en) 2013-03-15 2018-11-21 美商梅琳塔有限責任公司 Methods of treating infections in overweight and obese patients using antibiotics
BR112016012053A2 (en) * 2013-11-26 2017-08-08 Wockhardt Ltd ANTIBACTERIAL COMPOSITIONS
US20170252351A1 (en) 2015-01-24 2017-09-07 Wockhardt Limited Antibacterial Compositions

Also Published As

Publication number Publication date
AU2017295866A1 (en) 2019-01-17
IL264232A (en) 2019-02-28
PH12019500083A1 (en) 2019-07-08
BR112019000453A2 (en) 2019-04-30
CA3028452A1 (en) 2018-01-18
EP3484472A1 (en) 2019-05-22
KR20190039137A (en) 2019-04-10
US10624899B2 (en) 2020-04-21
CN109715156A (en) 2019-05-03
JP2019527214A (en) 2019-09-26
US20180015100A1 (en) 2018-01-18
WO2018013870A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
SG11201811345TA (en) Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201811432WA (en) Rna for cancer therapy
SG11201804934PA (en) Novel Compounds
SG11201903514VA (en) Novel cd47 monoclonal antibodies and uses thereof
SG11201910191RA (en) A peptide capable of forming a gel for use in tissue engineering and bioprinting
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201810485SA (en) Substituted carbonucleoside derivatives useful as anticancer agents
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201808306PA (en) Treatment of cancer with tg02
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201901374WA (en) Antibiotic compounds
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201906222WA (en) Jak1 selective inhibitors
SG11201809100QA (en) Use of gram negative species to treat atopic dermatitis
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof